Hypoestoxide is under clinical development by Immune Modulation and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Hypoestoxide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hypoestoxide overview
Hypoestoxide is under development for the treatment of colon cancer, Parkinson's disease, inflammation, Leishmaniasis, malaria, simplexvirus (HSV1 and HSV2) and HIV infections. It is administered through the oral route. The drug candidate is an active constituent derived from plant Hypoestes rosea. It acts by targeting IkappaB kinase (IKK) and actin assembly.
Immune Modulation overview
Immune Modulation is a bio-medical start-up that has developed a radically novel plant-based drug with Anti-Cancer, Anti-Malaria, and Anti-Inflammation. The company is headquartered in Bloomington, California, United States.
For a complete picture of Hypoestoxide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
